NCT04922736
Patient Reported Outcomes With UVA-1 Therapy for Treatment of Sclerosing Skin Diseases
At risk: Primary completion moved at least 11 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 10 versions: 8 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary and study completion pushed from Jun 2026 to Jun 2027 Show 5 more changesShow less
- Eligibility criteria expanded, about 10 words
- Trial arms changed: 0 → 1
- Secondary endpoints: details revised at 5 of 5 entries
- Study description expanded, about 9 words
- Publications: details revised at 12 of 13 entries
- Minor Trial status: Enrolling by Invitation to Active, Not Recruiting
- Primary and study completion dates: Dec 2025 to Jun 2026
- Notable Primary and study completion dates: Dec 2024 to Dec 2025v7
- Minor Primary and study completion dates pushed to Dec 2024v6
- Notable Primary completion date: Jun 2023 to Jun 2024
- Study completion date: Sep 2023 to Sep 2024
Show 2 earlier versionsHide 2 earlier versions
- Notable Trial status: Not Yet Recruiting to Enrolling by Invitation
- Study sites: 0 to 1
- Start date changed from estimate of Jun 2021 to Jun 7, 2021
- Minor Study description shortened, about 17 wordsv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (5)
Arms and interventions
All enrolled participants will receive UVA-1 phototherapy using a UVA-1 light box two to three times per week for a total of 30 treatment sessions over a 100-day period. The initial UVA-1 dose and subsequent dose increases will be determined according to usual clinical practice and the participant's type of sclerotic disease. Treatment will be held for active redness, burning, pain, or blistering at the treatment site. If symptoms have resolved by the next scheduled treatment, the UVA-1 energy will be reduced by 10 J from the previously delivered dose. Dose escalation may resume after three well-tolerated treatments.
Devices: UVA-1 Phototherapy
Sites
1 site in 1 country
- University of Utah DermatologyMurray, Utah, United States